A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia

被引：0

作者：

Dahir, Kathryn ^{[1
]}

Dunn, Derek ^{[2
]}

Hasan, Jawad ^{[2
]}

Shannon, Amy ^{[2
]}

Pan, Wei-Jian ^{[2
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Alexion, AstraZeneca Rare Dis, Boston, MA USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2023年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SUN-492

引用

页码：374 / 374

页数：1

共 50 条

[41] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
Croop, R.
Stringfellow, J.
Ivans, A.
Coric, V
HEADACHE, 2019, 59 : 177 - 178
[42] A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF A SINGLE DOSE OF DAZODALIBEP IN HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS
Der, K.
Wang, Z.
Bosoro, L.
Hewitt, L.
Wilson, T.
Huang, J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S79 - S79
[43] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study
Bhardwaj, Rajinder
Morris, Beth
Bertz, Richard
Croop, Robert
Liu, Jing
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (01): : 37 - 44
[44] PHYSOSTIGMINE IMPROVES CONFRONTATION NAMING IN 2 PATIENTS WITH ANOMIC APHASIA IN AN OPEN-LABEL, DOSE-ESCALATING STUDY
JACOBS, DH
ADAIR, JC
GOLD, M
SHUREN, J
WILLIAMSON, DJ
GONZALEZROTHI, L
HEILMAN, KM
BRAIN AND LANGUAGE, 1994, 47 (03) : 532 - 535
[45] Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study
Yani Liu
Jianhong Wu
Zhongfang Li
Ying Luo
Fandian Zeng
Shaojun Shi
European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 37 - 48
[46] A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin Levels in Normal Adult Volunteers
Schwabe, Christian
Hamilton, James
Christianson, Dawn
Kolbe, Jonathan
Teckman, Jeffrey H.
Gane, Edward J.
HEPATOLOGY, 2018, 68 (06) : 1451A - 1452A
[47] CARDINAL: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Chronic Myeloid Leukemia
Jabbour, Elias
Rea, Delphine
Cortes, Jorge
Hochhaus, Andreas
Hughes, Timothy
Kim, Dong-Wook
Kantarjian, Hagop
Holes, Leanne
Kuriakose, Emil
Mauro, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S370 - S371
[48] Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors
Lassen, Ulrik
Mau-Sorensen, Morten
Buhl, Ulla Hald
Madsen, Mogens W.
Balslev, Eva
Pluim, Dick
Schellens, Jan H. M.
Knudsen, Steen
Jensen, Peter B.
CANCER RESEARCH, 2016, 76
[49] Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study
Liu, Yani
Wu, Jianhong
Li, Zhongfang
Luo, Ying
Zeng, Fandian
Shi, Shaojun
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (01) : 37 - 48
[50] Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Garadacimab (CSL312) in Healthy Japanese and Caucasian Adults
Glassman, Fiona
Goodson, Summer
Bica, Alex
Roberts, Anthony
Akama, Hideto
Asami, Yumiko
Jain, Meena
Acharya, Milin
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB144 - AB144

← 1 2 3 4 5 →